Organogenesis Apligraf
This article was originally published in The Gray Sheet
Executive Summary
Novartis Pharma is set to resume shipments of the bi-layered, living skin substitute under an agreement announced Nov. 20. Novartis suspended its distribution in September after the companies failed to agree on an amended arrangement ("1The Gray Sheet" Sept. 30, 2002, In Brief). Under the new arrangement, the licensing and distribution rights to Apligraf will revert to Organogenesis in June 2003. Subject to approval of a Boston bankruptcy court, the deal is part of a Chapter 11 reorganizing plan filed by Organogenesis in September...
You may also be interested in...
Organogenesis
Return of Apligraf bi-layered, living skin substitute to the market will be sought under a chapter 11 bankruptcy reorganization plan filed Sept. 25 in Boston federal court. An exclusive distribution pact with Novartis was terminated earlier this month when the parties failed to agree on an amended arrangement (1"The Gray Sheet" Sept. 16, 2002, In Brief). The Canton, Massachusetts firm's workforce was subsequently cut from 125 to 15...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.